OR WAIT null SECS
October 24, 2019
Takeda Pharmaceutical Company has acquired an exclusive global license from COUR Pharmaceuticals for the development and commercialization of an investigational celiac disease therapy.
Sartorius has signed an agreement for the acquisition of parts of Danaher’s Life Science Portfolio in cash.
The therapy received positive results in a randomized, double-blind, placebo-controlled clinical trial in 34 adults with proven celiac disease.
The transaction is set to be completed in the first quarter of 2020.
October 22, 2019
The transaction is anticipated to close by the end of 2019.
October 21, 2019
During day two of CPhI Worldwide in Frankfurt, Germany, Informa Pharma Intelligence will host a roundtable discussion regarding recent and future mergers and acquisitions.
October 16, 2019
The transaction gives Alexion access to Achillion’s portfolio of oral small-molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases.
October 11, 2019
The transaction is set to be completed at the end of the first quarter of 2020.
October 10, 2019
MilliporeSigma will now be the first company to make acoustic technology available for cell therapy manufacturing.
October 09, 2019
The acquisition comes after Bormioli became an independent company owned by Triton Investment Fund in December 2017.